Key Takeaways
- Fibromyalgia Impact Questionnaire scores dropped by roughly 30% after ten sessions of major ozone therapy, a statistically significant reduction.
- Eye pressure, corneal thickness, visual acuity, and retinal microvascular density all remained stable throughout treatment, suggesting no short-term ocular risk.
- Researchers describe ozone therapy as a potential complementary approach alongside existing fibromyalgia treatments, not a standalone cure.
A 30% drop in symptom burden is a meaningful number in fibromyalgia research, where even modest improvements can translate to real shifts in daily functioning. That is what a small but carefully monitored observational study found after putting 30 fibromyalgia patients through ten weekly sessions of major ozone therapy. Published results show the treatment produced a statistically significant reduction in overall disease impact — and, notably, left the eyes completely unaffected.
Fibromyalgia Impact Questionnaire scores fell from 67.19 to 46.78 after treatment — a reduction of more than 20 points, significant at p < 0.001.
Researchers also tracked a full panel of eye health markers, none of which changed meaningfully during the treatment course.
Major ozone therapy involves mixing a patient's drawn blood with medical-grade ozone gas before returning it to the body — a process thought to modulate immune activity and reduce oxidative stress. Because ozone is a highly reactive molecule, there has been reasonable scientific interest in whether repeated treatments could affect sensitive vascular structures, including the tiny blood vessels at the back of the eye. The study's authors used optical coherence tomography angiography, a high-resolution imaging technique, to examine those retinal vessels in detail before and after treatment.
Think of the retina's capillary network as a live map of how ozone therapy interacts with the body's smallest blood vessels — if the treatment were causing vascular stress anywhere, the eye would likely show it first. In this study, it showed nothing: intraocular pressure held steady at roughly 15 mmHg both before and after treatment, central corneal thickness barely shifted, and measurements of retinal blood vessel density in both superficial and deep capillary layers remained statistically unchanged. Best-corrected visual acuity stayed at 1.0 — perfect — across both assessments.
The study carries real limitations: 30 patients, no control group, and a short ten-week window make it impossible to draw firm conclusions about long-term safety or efficacy. Fibromyalgia is also a notoriously difficult condition to treat, and placebo effects on self-reported symptom scales can be substantial. Still, the dual focus — measuring both symptom relief and potential ocular harm simultaneously — gives the findings an unusual degree of practical relevance for clinicians and patients considering ozone therapy as an add-on to standard fibromyalgia care. For a field still searching for reliable complementary options, that pairing of benefit and documented safety, even in a preliminary sample, adds something of value to the conversation.
Major ozone therapy improves disease severity without affecting retinal microvascular parameters in fibromyalgia syndrome: an observational pre-post study.
Medical Disclaimer: The information provided on ChronicRelief.org is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.